An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder.

Eli Lilly’s anti-diabetic medication Zepbound cuts the risk of developing Type 2 diabetes by 94 percent in pre-diabetic adults and or those who are overweight or obese, the company said Tuesday.

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt to help with their weight loss efforts. Ozempic is actually for type-2 ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

China’s nascent weight loss drug market is poised for rapid growth, with analysts estimating it could grow to between US$5.6 billion (S$7.2 billion) and US$11.4 billion a year.